ITM to Participate in Upcoming Investor Conferences
11. November 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, November 11, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor...
ITM, TUM und das TUM Universitätsklinikum unterzeichnen eine neue Rahmenvereinbarung zur Entwicklung innovativer radiopharmazeutischer Krebstherapien
24. Oktober 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / München, 24. Oktober 2024 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Unternehmen, die Technische Universität München (TUM) und das TUM...
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
24. Oktober 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM...
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
18. Oktober 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an additional manufacturing and supply...
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
19. September 2024 05:22 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry...
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
12. September 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452)...
ITM ernennt Dr. Andrew Cavey zum CEO, um das weitere Wachstum des Unternehmens voranzutreiben
20. Juni 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Dr. Cavey verfügt über langjährige Berufserfahrung in der radiopharmazeutischen Industrie und wird die Weiterentwicklung von ITMs Pipeline und das Unternehmenswachstum maßgeblich unterstützen....
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
20. Juni 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
With a significant track record of success in the radiopharmaceutical industry, Dr. Cavey will help accelerate ITM’s pipeline and business growth Garching /...
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
06. Juni 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
07. Mai 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Leveraging profound knowledge in radiopharmaceutical drug development and commercial planning, Dr. Meyrick will lead the medical team in further developing and delivering on ITM's pipeline...